Moleculin Biotech (NASDAQ: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, has closed an underwritten public offering of an aggregate of 16,414,736 shares of common stock, including an additional 2,141,052 shares per the full exercise of the over-allotment option granted to the underwriters. According … Continue reading “NetworkNewsBreaks – Moleculin Biotech Inc. (NASDAQ: MBRX) Secures $78M in Underwritten Public Offering”
Moleculin Biotech, Inc. (NASDAQ: MBRX) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “MBRX outlined its 2020 goals this morning, emphasizing its focus on lead drug annamycin (in Phase 1 for AML) and WP1220 (recently completed Phase 1 for CTCL). A recent $6 million financing gives … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Featured in ROTH Equity Research Report”
Moleculin Biotech, Inc. (NASDAQ: MBRX) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Late last week, MBRX presented final Phase 1b results at the 4th Annual World Congress of Cutaneous Lymphomas, demonstrating median reduction of 56% in the CAILS score of index skin lesions in a … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Featured in ROTH Equity Research Report”
Moleculin Biotech (NASDAQ: MBRX) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, MBRX announced the successful conclusion to its open label, single arm U.S. Phase 1 liposomal annamycin trial, having achieved a highly favorable safety profile in relapsed or refractory AML, as well as clear … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Featured in ROTH Equity Research Report”
Moleculin Biotech (NASDAQ: MBRX) is a clinical-stage pharmaceutical company focused on development of oncology drug candidates based on discoveries at M.D. Anderson Cancer Center. The company’s clinical-stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia … Continue reading “Moleculin Biotech Inc. (NASDAQ: MBRX) Attends 31st Annual ROTH Conference”
Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has WP1066 … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at 30th Annual ROTH Conference”
Clinical stage pharmaceutical company Moleculin Biotech (NASDAQ: MBRX) has closed its offering of 4.29 million registered shares of common stock at a purchase price of $2.10 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, the investor will receive an unregistered warrant to purchase 0.5 of a … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Closes $9M Registered Direct Offering”
Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has two … Continue reading “Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event”
Shares of Moleculin Biotech (NASDAQ: MBRX) are trading 7% higher this morning following the company’s news that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to study Annamycin in the treatment of relapsed or refractory acute myeloid leukemia (AML). The company expects the FDA will allow the IND to … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia”
Shares of Moleculin Biotech (NASDAQ: MBRX) are up 9% mid-day following the company’s comments regarding the recent FDA approvals for new drugs for the treatment of acute myeloid leukemia (AML). The company’s drug candidate, Annamycin, is currently being evaluated for the treatment of relapsed or refractory AML. “While these new drugs make valuable incremental improvements … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia”
